Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VISION

Financiado

Virus Inhibition by siRNA Optimized by NMR

The last two years, profoundly marked by the COVID-19 sanitary crisis, have demonstrated the difficulties to answer adequately to the emergence of novel pathogenic viruses. Today, no broad-spectrum antiviral exists similar to anti... ver más

29/02/2024

CNRS

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

CNRS

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121255-I00 UNA NUEVA PLATAFORMA ANTIVIRAL BASADA EN ARN: PRUEBA DE CONC... 133K€ Cerrado

NAVIPP New AntiVirals for Infections with Pandemic Potential 6M€ Cerrado

Inhibicov Hit-to-Lead Development of potent broad-spectrum coronavirus... 150K€ Cerrado

PID2020-113888RB-I00 DESORGANIZACION MOLECULAR DURANTE LA MUTAGENESIS LETAL DE SA... 157K€ Cerrado

FLUIDITY Fighting Large-Scale Untreated Infectious Diseases with Inno... 5M€ Cerrado

Fight-nCoV FIGHTING OFF CORONAVIRUS SARS CoV 2 WITH BROAD SPECTRUM AN... 3M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-08-16
Fecha Fin: 2024-02-29

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto The last two years, profoundly marked by the COVID-19 sanitary crisis, have demonstrated the difficulties to answer adequately to the emergence of novel pathogenic viruses. Today, no broad-spectrum antiviral exists similar to antibiotics targeting bacteria. Repositioning of existing molecules had limited success despite intense initial hopes. Vaccines have played a major role in fighting the pandemic and limiting the impact of the virus, however it remains insufficient to end the pandemic, due to many factors including their worldwide uneven accessibility, their intrinsic efficiency towards different variants and the complex socio-political context related to mass vaccination. There is therefore an urgent need of novel approaches to design molecules targeting viruses and in particular SARS-CoV-2. To answer this challenge, we propose a novel strategy derived from fundamental research on small interfering RNA (siRNA). This project derives from the ERC Starting Grant PARAMIR, in which novel structural biology approaches are proposed to understand the mechanism of recognition of a similar class of RNA involved in numerous diseases, especially cancer. Our approach combines the latest advances in SARS-CoV-2 virology and structural biology to propose efficient and specific molecules active towards a broad range of SARS-CoV-2 current and future variants. If successful the project will lead to a class of siRNA, with optimized specificity and stability, validated in vitro and ex-vivo in a reconstituted human airway epithelial model, and ready for testing towards pre-clinical and clinical stage. Finally, the strategy proposed here will be on a longer term applicable to multiple other pathogenic viruses.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores